CRISPR-Cas technology: Targeted Genome Editing Technology

Through the years, many promising tools for genome editing have been developed including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-associated protein 9 (Cas9). ZFN and TALENs target genome modification methods, design is costly and time-consuming, limiting their widespread use, especially for large-scale, high-throughput studies. CRISPR-Cas9 is a unique technology that enables geneticists and medical researchers to study, alter, create, and recreate highly complex pathways, DNA sequences, genes, and natural biological systems. It is currently the simplest, most versatile, and precise   method of genetic manipulation and is therefore causing a buzz in the science world3. It has been widely used in the study of genome editing in broad applications such as stem cell engineering, gene therapy, tissue and animal disease models, and engineering disease-resistant transgenic plants, which has greatly improved the understanding of tumor genomics in people.

Products

⭐ ⭐ ⭐ ⭐ ⭐ Products Recommendations

ACROBiosystems focuses on the field of cell and gene therapy. As a leading supplier of recombinant proteins, ACROBiosystems has launched the CAS series nuclease including Cas9 and Cas12a. These proteins are mainly used for targeted gene editing to provide high editing efficiency.

Product Features:

The high enzyme activity is verified by in vivo/in-vitro experiments: In-vitro fragment cleavage efficiency >90%, which is facilitating genome editing with CRISPR technology.
Available in high concentrations of CAS-9 nuclease:10mg/ml for optimization of editing conditions in more difficult scenarios
High purity:SDS-PAGE & SEC-MALS verified purity > 90%.
Incorporation of nuclear localization signals (NLS) aids delivery to the nucleus, increasing the rate of genomic DNA cleavage
No residual RNase: The production process is strictly free from RNase pollution
Enzyme activity and purity have been inspected in batches. High stability and consistency between batches.

The interactions between prokaryotes and the viruses that infect them have evolved, leading to a wide diversity of CRISPR-Cas systems. CRISPR-Cas systems are generally divided into two categories (Class 1 and Class 2). To date, most researchers have used the Type 2 CRISPR-Cas system, and in this class, the most studied type II is the CRISPR-Cas9 system.

CRISPR-Cas9 related applications
Applications in CAR-T therapy:
1) Generation of universal allogeneic CAR-T cells; 2) Enhancement of CAR-T cell function

Application of TCR-T cell therapy:
α and β endogenous TCR Gene replacement with artificial tumor-specific TCR sequences for genes

Suppression of immune checkpoint signaling pathways
Screening of new targets for tumor immunotherapy
How does CRISPR-Cas9work

CRISPR/Cas9 system involves two essential components: target-specific CRISPR gRNA and Cas9 nuclease. In eukaryotic systems, CRISPR/Cas9 is used for genomic editing through specific targeting of DNA by sgRNA, a combination of the CRISPR RNA (crRNA) and the trans-activating crRNA (tracrRNA), mediated through base pairing over the ~20-nt guide sequence [1]. Cas9 recognizes a very short conserved sequence (a few nucleotides in length) adjacent to the guide sequence called the “protospacer adjacent motif” (PAM). Once directed to the DNA target site, Cas9 generates a double-strand break (DSB) that can be repaired either through the indel mutation-introducing non-homologous end-joining (NHEJ) or the high-fidelity homologous directed repair (HDR), resulting in gene knockout effects or template-dependent gene replacement.

CRISPR-Cas9 mechanism of action CRISPR-Cas9 regulatory mechanism: Repair of double-stranded DNA breaks by non-homologous end ligation (NHEJ) or homologous directed repair (HDR) endogenously[1]

Assay Data

High Purity: >95% purity verified by SEC-HPLC
High Purity: >95% purity verified by SEC-HPLC

The purity of GMP GENPower™ NLS-Cas9 Nuclease (Cat. No. GMP-CA9S18) was greater than 95% as determined by SEC-HPLC.

High Activity: Plasmid cleavage efficiency >90%; TCR knockout in human primary T cells >95%; highly efficient cleavage demonstrated in HEK293, iPSC, and primary T cells (B2M)
High Activity: Plasmid cleavage efficiency >90%

Different amounts of Cas9 were incubated with the same amount of excess gRNA and plasmid for 60 minutes at 37°C. When using 400-200 ng ACRO's Cas9, the cutting efficiency is greater than 90% (QC tested). In comparison, when using a 200 ng CAS9 from company T, the cutting efficiency is only about 50%

High Activity: Plasmid cleavage efficiency >90%

The TCR knockout efficiency with GMP GENPower™ NLS-Cas9 Nuclease in human primary T cells, GMP GENPower™ NLS-Cas9 Nuclease achieved over 95% knockout efficiency.

High Activity: Plasmid cleavage efficiency >90%

The cleavage efficiency in HEK293 cell 72 hours after electroporation of GMP GENPower™ NLS-Cas9 Nuclease RNP.

High Activity: Plasmid cleavage efficiency >90%

The cleavage efficiency in iPSC 72 hours after electroporation of GMP GENPower™ NLS-Cas9 Nuclease RNP.

High Activity: Plasmid cleavage efficiency >90%

The knockout efficiency for B2M in primary T cell was measured by Flow Cytometry.

Stability: Enzyme activity remains stable for 35 days at 37°C, with excellent batch-to-batch consistency
Stability: Enzyme activity remains stable for 35 days at 37°C, with excellent batch-to-batch consistency

Enzymatic activity assay demonstrates that GMP GENPower™ NLS-Cas9 Nuclease (Cat. No. GMP-CA9S18) is stable at 37°C for 35 days

Stability: Enzyme activity remains stable for 35 days at 37°C, with excellent batch-to-batch consistency

Enzymatic activity assay demonstrates batch-to-batch consistency between Acro's GMP and PG Cas9.

References

  • 1. Westermann L, Neubauer B, Köttgen M. Nobel Prize 2020 in Chemistry honors CRISPR: a tool for rewriting the code of life. Pflugers Arch. 2021 Jan; 473(1):1-2.

  • 2. Application of CRISPR/Cas9 gene editing in tumor immunotherapy

  • 3. Zaib S, Saleem MA, Khan I. CRISPR-Cas9 Genome Engineering: Trends in Medicine and Health. Mini Rev Med Chem. 2022;22(3):410-421. doi: 10.2174/1389557521666210913112030. PMID: 34517795.

  • Background
  • Products
  • Product List
  • Assay Data
  • References
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호